6 completed. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 2 | Completed 2 |
Follow berzosertib: new trials by email Literature Review of berzosertib trials Research Report on berzosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208) [14C]Berzosertib, Berzosertib, Topotecan - Advanced Solid Tumor | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 6 | 2022-02-15 | 2024-11-22 |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors Berzosertib, Sacituzumab Govitecan - HRD Cancer, SCLC | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 35 | 2021-09-20 | 2026-07-21 |
| ATRi Transition Rollover Study Berzosertib - Advanced Stage Solid Tumors | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 1 | 2018-01-10 | 2024-11-29 |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors Veliparib + VX-970 + Cisplatin - Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 53 | 2017-08-09 | 2022-02-08 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers Topotecan, VX-970 (M6620) - Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 62 | 2015-07-30 | 2025-04-13 |
| M6620 First in Human Study M6620, Gemcitabine, Cisplatin - Advanced Solid Tumor | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 200 | 2012-12-10 | 2020-04-01 |
Hereditary Sensory and Autonomic Neuropathies (2) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1) · Uterine Cervical Neoplasms (1)
National Cancer Institute (NCI) (3) · EMD Serono Research & Development Institute, Inc. (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1)
United States (4) · United Kingdom (2) · Hungary (1)
Anish Thomas, M.D. (2) · Alice P Chen, M.D. (1)
PMID 29252124, PMID 33145616, PMID 34040174, PMID 34040175, PMID 34904813, PMID 40437704, PMID 40669022, PMID 42820295
2017 (1)